LT3423042T - Liofilizuota farmacinė vaisto forma ir jos panaudojimas - Google Patents

Liofilizuota farmacinė vaisto forma ir jos panaudojimas

Info

Publication number
LT3423042T
LT3423042T LTEPPCT/FI2017/050128T LTFI2017050128T LT3423042T LT 3423042 T LT3423042 T LT 3423042T LT FI2017050128 T LTFI2017050128 T LT FI2017050128T LT 3423042 T LT3423042 T LT 3423042T
Authority
LT
Lithuania
Prior art keywords
pharmaceutical form
lyophilized pharmaceutical
lyophilized
pharmaceutical
Prior art date
Application number
LTEPPCT/FI2017/050128T
Other languages
English (en)
Inventor
Markku Jalkanen
Mikael Maksimow
Ilse Piippo
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Publication of LT3423042T publication Critical patent/LT3423042T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/215IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/565IFN-beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
LTEPPCT/FI2017/050128T 2016-02-29 2017-02-28 Liofilizuota farmacinė vaisto forma ir jos panaudojimas LT3423042T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20165153A FI126979B (en) 2016-02-29 2016-02-29 Lyophilized pharmaceutical formulation and its use
PCT/FI2017/050128 WO2017149199A1 (en) 2016-02-29 2017-02-28 A lyophilised pharmaceutical formulation and its use

Publications (1)

Publication Number Publication Date
LT3423042T true LT3423042T (lt) 2022-08-10

Family

ID=58347412

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/FI2017/050128T LT3423042T (lt) 2016-02-29 2017-02-28 Liofilizuota farmacinė vaisto forma ir jos panaudojimas

Country Status (23)

Country Link
US (1) US10293030B2 (lt)
EP (1) EP3423042B1 (lt)
JP (1) JP6869255B2 (lt)
KR (1) KR102821435B1 (lt)
CN (2) CN107921001A (lt)
AU (1) AU2017225236B2 (lt)
BR (1) BR112018016545B1 (lt)
CA (1) CA3011609C (lt)
CY (1) CY1125375T1 (lt)
DK (1) DK3423042T3 (lt)
ES (1) ES2922481T3 (lt)
FI (1) FI126979B (lt)
HK (1) HK1250147A1 (lt)
HR (1) HRP20220896T1 (lt)
HU (1) HUE059550T2 (lt)
LT (1) LT3423042T (lt)
PL (1) PL3423042T3 (lt)
PT (1) PT3423042T (lt)
RS (1) RS63429B1 (lt)
SI (1) SI3423042T1 (lt)
SM (1) SMT202200281T1 (lt)
WO (1) WO2017149199A1 (lt)
ZA (1) ZA201804835B (lt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6043627B2 (ja) * 2009-06-25 2016-12-14 ルバンス セラピュティックス インク.Revance Therapeutics,Inc. アルブミン非含有ボツリヌス毒素製剤
US9913880B2 (en) * 2011-02-18 2018-03-13 Stemdr Inc. Method of treating sepsis or septic shock
PY1939780A (es) * 2018-05-25 2019-12-04 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
KR20230136119A (ko) 2021-01-25 2023-09-26 파론 파머수티컬스 오와이 Cd73을 상향 조절할 수 있는 약제 및 글루코코르티코이드의순차적 투여를 사용한 질환의 치료

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0150067A3 (en) 1984-01-23 1986-12-30 Takeda Chemical Industries, Ltd. Stable composition of gamma-interferon
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US5556771A (en) 1995-02-10 1996-09-17 Gen-Probe Incorporated Stabilized compositions of reverse transcriptase and RNA polymerase for nucleic acid amplification
DK1017413T4 (da) 1997-09-23 2008-03-25 Rentschler Biotech Gmbh Flydende formulering af interferon-beta
JP2001312910A (ja) * 2000-04-28 2001-11-09 Sanyo Electric Co Ltd 太陽光採光装置
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
BR0312947A (pt) 2002-07-17 2007-07-10 Biogen Idec Inc terapias para insuficiência renal empregando-se interferon-beta
EP1608400B1 (en) 2003-03-28 2010-06-23 Faron Pharmaceuticals OY Elevation of adenosine level by cytokine-induced expression of cd73
AR044302A1 (es) 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
AU2004248931B2 (en) * 2003-06-20 2009-07-16 Ares Trading S.A. Freeze-dried FSH / LH formulations
DE602005022895D1 (de) * 2004-08-12 2010-09-23 Schering Corp Stabile pegylierte interferon-formulierung
US20120269770A1 (en) 2010-11-22 2012-10-25 Mark Brader Stable Preserved Compositions of Interferon-Beta

Also Published As

Publication number Publication date
ES2922481T3 (es) 2022-09-15
CA3011609C (en) 2023-10-10
HK1250147A1 (zh) 2018-11-30
JP6869255B2 (ja) 2021-05-12
CY1125375T1 (el) 2025-05-09
KR20180114018A (ko) 2018-10-17
EP3423042A1 (en) 2019-01-09
CN115364060A (zh) 2022-11-22
WO2017149199A1 (en) 2017-09-08
RS63429B1 (sr) 2022-08-31
KR102821435B1 (ko) 2025-06-17
BR112018016545A2 (pt) 2018-12-26
EP3423042B1 (en) 2022-04-27
US20170246254A1 (en) 2017-08-31
AU2017225236A1 (en) 2018-08-02
BR112018016545B1 (pt) 2023-10-10
CN107921001A (zh) 2018-04-17
CA3011609A1 (en) 2017-09-08
FI126979B (en) 2017-09-15
HRP20220896T1 (hr) 2022-10-14
FI20165153A7 (fi) 2017-08-30
JP2019513123A (ja) 2019-05-23
AU2017225236B2 (en) 2022-03-31
PT3423042T (pt) 2022-07-25
US10293030B2 (en) 2019-05-21
DK3423042T3 (da) 2022-07-18
SMT202200281T1 (it) 2022-09-14
PL3423042T3 (pl) 2022-09-19
ZA201804835B (en) 2024-09-25
HUE059550T2 (hu) 2022-11-28
SI3423042T1 (sl) 2022-10-28

Similar Documents

Publication Publication Date Title
IL285286A (en) Transposase polypeptides and uses thereof
EP3563863A4 (en) LYOPHILIZED PREPARATION
FI3494134T3 (fi) Muunneltuja polypeptidejä ja niiden käyttötapoja
LT3453707T (lt) Benzazepino darinys, gamybos būdas, farmacinė kompozicija ir jos naudojimas
HUE055311T2 (hu) Módosított FGF-21 polipeptidek és azok felhasználása
LT3448386T (lt) Izochinolin-3-ilo karboksamidai ir jų gamyba bei naudojimas
LT3317284T (lt) Benzoksazepino oksazolidinono junginiai ir jų naudojimo būdai
LT3280441T (lt) Anti-sortilino antikūnai ir jų naudojimo būdai
LT3368534T (lt) Valbenazino ditozilatas ir jo polimorfai
LT3333191T (lt) Anti-c10orf54 antikūnai ir jų panaudojimas
IL248979B (en) Syntac polypeptides and uses thereof
LT3116909T (lt) Antikūno molekulės prieš lag-3 ir jų panaudojimas
LT3215532T (lt) Anti-tim3 antikūnai ir jų naudojimo būdai
HUE062189T2 (hu) Aktivin-ACTRII-antagonisták és alkalmazások mielodiszpláziás szindróma kezelésére
LT3137114T (lt) Anti-ptk7 antikūnų ir vaistų konjugatai
LT3394065T (lt) Tetrahidropiranilamino-pirolopirimidinonas ir jo panaudojimo būdai
EP3465539A4 (en) Synchronized surface and internal tumor detection
LT3319612T (lt) Oksisteroliai ir jų naudojimo būdai
LT3484865T (lt) Somatostatino moduliatoriai ir jų panaudojimas
LT3498292T (lt) Uspa2 baltymo konstruktai ir jų panaudojimas
LT3128005T (lt) Sirp-alfa varianto konstruktai, ir jų panaudojimas
EP3391768A4 (en) VELCRO STRIP AND TEXTILE PRODUCTS
LT3672948T (lt) Piridinamino-piridono ir pirimidinamino-piridono junginiai
EP3498535A4 (en) LIGHTING AND SENSOR SYSTEM
LT3197898T (lt) Nauji imidazopiridazino junginiai ir jų panaudojimas